Peptides and cancer risk: separating real warnings from biohacker hype

What did @karinasbiohacking actually say?

The creator said she gets a lot of questions from people "with a history of cancer" and has compiled a list of peptides they should avoid. She's offering this list as a free PDF through her store link. She mentions PNC-27 specifically as a peptide she's previously covered, and frames the video primarily as a lead-generation post for her digital products. She doesn't actually name any specific peptides in the video itself.

To be clear about what this video is and isn't: it's a teaser. No specific claims about which peptides are dangerous, no mechanisms explained, no sources cited. The entire substance of her argument is behind a link. That matters for how we evaluate it.

Does the science back this up?

The general premise, that some peptides warrant caution in people with a cancer history, is scientifically legitimate. Growth-promoting peptides in particular have real mechanistic reasons for concern. But the evidence quality varies enormously depending on which peptide you're talking about.

Growth hormone secretagogues like CJC-1295 and ipamorelin work by increasing IGF-1 levels. Elevated IGF-1 is associated with increased risk of several cancers, including prostate and colorectal, based on epidemiological data (Renehan et al., 2004, The Lancet). That's a reasonable basis for caution in cancer survivors. BPC-157 presents a more complicated picture. It promotes angiogenesis and tissue repair, and while some animal studies show tumor-suppressive effects, others raise concerns about accelerating tumor growth by supporting vascularization. The honest answer is we don't have good human trial data. GHK-Cu has shown antitumor signaling properties in some lab studies, but again, translating that to clinical recommendations is premature.

What did they get wrong (or right)?

Credit where it's due: flagging this topic at all is more responsible than most peptide content on TikTok, which tends to be pure enthusiasm. The general warning is directionally correct.

But there are real problems here. First, she mentions PNC-27 approvingly as context. PNC-27 is an experimental peptide claimed to selectively kill cancer cells. The evidence base for this is extremely thin, mostly in vitro work, and there are no completed human trials. Treating it as a legitimate cornerstone of peptide therapy for cancer patients is a stretch that requires a lot more than a TikTok mention.

Second, and more importantly, delivering nuanced oncology-adjacent guidance through a PDF sold via a "Stan store" is not how this information should travel. Cancer survivors have oncologists. The correct path for peptide questions isn't a cheat sheet from a biohacker, it's a conversation with a provider who knows their specific cancer type, treatment history, and current health status. Collapsing all "history of cancer" into one list ignores the enormous clinical differences between, say, an ER-positive breast cancer survivor five years post-treatment versus someone in active treatment for a growth hormone-sensitive tumor.

What should you actually know?

If you have a history of cancer and you're interested in peptide therapy, a few things are worth understanding before you go anywhere near a PDF list.

• Growth hormone-stimulating peptides, including MK-677, CJC-1295, and ipamorelin, raise IGF-1. IGF-1 is a legitimate concern in hormone-sensitive cancers. This isn't fearmongering, it's basic endocrinology (Pollak, 2008, Nature Reviews Cancer).
• BPC-157's relationship with cancer is genuinely unresolved. Some researchers see potential anti-inflammatory benefits; others point to its pro-angiogenic effects as a red flag. Anyone telling you definitively which way this goes is ahead of the data.
• TB-500 (thymosin beta-4) promotes cell migration and angiogenesis. The same properties that help tissue heal could theoretically support tumor progression. No human data exists on this question.
• "History of cancer" is not a single category. A peptide that might be acceptable for one cancer type, stage, and treatment history could be genuinely problematic for another. A list cannot capture that.

The bottom line is that the creator's instinct to add caution to this space is correct. But a free PDF from a biohacking influencer is not a substitute for individualized medical guidance from a provider with access to your actual records.